When was NeOnc Technologies founded?

NeOnc Technologies was founded in 2008 and raised its 1st funding round 1 year after it was founded.

Where is NeOnc Technologies located?

NeOnc Technologies is headquartered in Los Angeles, United States.

How many employees does NeOnc Technologies have?

As of Jul 01, 2024, the latest employee count at NeOnc Technologies is 2.

Is NeOnc Technologies a funded company?

NeOnc Technologies is a funded company, having raised a total of $18.7M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 17, 2009.

When was the latest funding round of NeOnc Technologies?

NeOnc Technologies' latest funding was a $***** Grant (prize money) round on Aug 07, 2025, with participation from 1 investor. Its primary sector is Drug Delivery. In United States, the Drug Delivery sector has seen $196M in funding in 2026 to date.

Where does NeOnc Technologies rank among its competitors?

NeOnc Technologies ranks 267th amongst 3332 active competitors, of which 1140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of NeOnc Technologies?

NeOnc Technologies' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

NeOnc Technologies - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drug delivery methods for pharma-based therapeutics. The company develops intranasal inhalation of perillyl alcohol for the treatment of malignant brain cancer (gliomas). The company has secured worldwide rights to NEO100, a purified version of perillyl alcohol, and has obtained approval from the FDA to perform clinical trials in patients with recurrent Grade 4 glioma.

Key Metrics

Founded Year

2008

Location

Los Angeles, United States

Stage

Public

Total Funding

$18.7M in 7 rounds

Latest Funding Round

Grant (prize money), Aug 07, 2025, $*****

Investors

NIH & 1 more

Ranked

267^th among 3332 active competitors

Employee Count

2 as on Jul 01, 2024

Similar Companies

Jazz Pharmaceuticals & 3057 more

Exit Details

Public

View NeOnc Technologies' full profile

NeOnc Technologies is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neonc Technologies, Inc. CIN: 1478689 , United States, Active		$1M - $5M (As on Feb 22, 2013)	-	-

NeOnc Technologies got listed on Mar 26, 2025.

Click here to take a look at NeOnc Technologies's IPO in detail

NeOnc Technologies has raised a total funding of $18.7M over 7 rounds. Its first funding round was on Dec 17, 2009. Its latest funding round was a Grant (prize money) round on Aug 07, 2025 for $*****. 1 investor participated in its latest round. NeOnc Technologies has 2 institutional investors.

Here is the list of recent funding rounds of NeOnc Technologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 07, 2025	6003799	Grant (prize money)	2770610	9986694	6650975	2041174
Jul 15, 2024	3453522	Series A	1433004	7063176	9289565	3287089
Feb 24, 2022	7392443	Seed	8668281	9115079	9267691	8533971

Access funding benchmarks and valuations. Sign up today!

View details of NeOnc Technologies's funding rounds and investors

The founders of NeOnc Technologies is Thomas Chen.

Here are the details of NeOnc Technologies' key team members:

Thomas Chen: Co-Founder of NeOnc Technologies.

View details of NeOnc Technologies's Founder profiles and Board Members

NeOnc Technologies' employee count trend

NeOnc Technologies has 2 employees as of Jul 24. Here is NeOnc Technologies's employee count trend over the years:

Employee count trend for NeOnc Technologies

Uncover NeOnc Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeOnc Technologies include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of NeOnc Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
267th	NeOnc Technologies 2008, Los Angeles (United States), Public	Developer of drug delivery methods for pharma-based therapeutics	$18.7M	NIH, S3 Capital	58/100